AOD-9604 vs Tesamorelin

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176-191) of human growth hormone, with an added tyrosine residue. Preclinical research has demonstrated its lipolytic activity independent of the full growth hormone signaling cascade, notably without stimulating IGF-1 production or affecting carbohydrate metabolism. This selective mechanism has made AOD-9604 a compound of significant interest in body composition and lipid metabolism research. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification. Unlike fragment-based peptides, tesamorelin stimulates the complete growth hormone axis by acting on GHRH receptors in the anterior pituitary, resulting in endogenous GH release and downstream IGF-1 elevation. It is studied in metabolic research contexts involving visceral adiposity and body composition parameters.

Attribute	AOD-9604	Tesamorelin
Structure	GH fragment 176-191 + Tyr	Full GHRH analog (44 amino acids + modification)
Mechanism	Direct lipolytic action; no IGF-1 stimulation	Stimulates endogenous GH release via GHRH receptor
IGF-1 Effect	No significant IGF-1 elevation	Increases IGF-1 through GH axis activation
Research Focus	Lipid metabolism, adipocyte biology	Visceral adiposity, full GH axis modulation
Selectivity	Highly selective (lipolysis only)	Broad (full GH cascade downstream effects)
Carbohydrate Impact	Minimal in preclinical models	GH-mediated effects on glucose metabolism
Study Model Context	Adipocyte models, body composition studies	Metabolic syndrome models, body composition studies

AOD-9604

Structure GH fragment 176-191 + Tyr

Mechanism Direct lipolytic action; no IGF-1 stimulation

IGF-1 Effect No significant IGF-1 elevation

Research Focus Lipid metabolism, adipocyte biology

Selectivity Highly selective (lipolysis only)

Carbohydrate Impact Minimal in preclinical models

Study Model Context Adipocyte models, body composition studies

Tesamorelin

Structure Full GHRH analog (44 amino acids + modification)

Mechanism Stimulates endogenous GH release via GHRH receptor

IGF-1 Effect Increases IGF-1 through GH axis activation

Research Focus Visceral adiposity, full GH axis modulation

Selectivity Broad (full GH cascade downstream effects)

Carbohydrate Impact GH-mediated effects on glucose metabolism

Study Model Context Metabolic syndrome models, body composition studies

The Verdict

AOD-9604 and tesamorelin represent two fundamentally different approaches to studying GH-related metabolic pathways. AOD-9604 isolates the lipolytic activity of growth hormone without engaging the broader GH-IGF-1 axis, making it valuable for researchers who need to study fat metabolism independent of confounding GH effects. Tesamorelin activates the full GHRH-GH-IGF-1 cascade, which is more appropriate for research models examining the complete spectrum of growth hormone biology including its effects on visceral adiposity. The choice between them depends entirely on whether the research question requires isolated lipolytic signaling or full axis engagement.

Explore These Products

AOD-9604

A synthetic peptide fragment of human growth hormone (amino acids 177-191) studied for its role in fat metabolism and lipolysis without affecting blood sugar or growth.

View Details →

Tesamorelin

A potent synthetic GHRH analog studied in preclinical models for its effects on visceral adipose tissue and body composition.

View Details →

AOD-9604 vs Tesamorelin — FAQ

Why does AOD-9604 not raise IGF-1 levels?

AOD-9604 is a small fragment of the growth hormone molecule that retains lipolytic signaling but lacks the structural domains responsible for GH receptor binding and IGF-1 stimulation. This selective activity allows researchers to study fat metabolism pathways without the confounding variable of IGF-1 elevation.

Does tesamorelin produce the same effects as exogenous growth hormone?

Tesamorelin stimulates endogenous GH release through the GHRH receptor rather than introducing exogenous GH. This preserves pulsatile GH secretion patterns and feedback mechanisms that are bypassed with direct GH administration, making it a physiologically distinct research tool.

Can AOD-9604 and tesamorelin be studied together?

They can be included in comparative study designs, but combining them would introduce overlapping pathways. More commonly, researchers use them independently to distinguish between isolated lipolytic effects and full GH axis-mediated metabolic changes.

References

Primary sources for key clinical and regulatory claims on this page.

A new anti-obesity compound, AOD9604, reduces body weight in obese Zucker rats by stimulating lipolysis — PubMed / Int J Obes Relat Metab Disord . Primary preclinical source for AOD-9604 lipolytic mechanism and body composition effects without IGF-1 stimulation.
Tesamorelin, a human growth hormone releasing factor analogue: pharmacology and clinical studies — PubMed / Expert Opin Investig Drugs . Comprehensive review of tesamorelin pharmacology and its role as a GHRH analog in metabolic research.

Keep Researching

Use the surrounding category and guide pages to move from a side-by-side comparison into the broader decision path.

Research Peptides Category Growth-Hormone Hub

Updated March 2026. This comparison is reviewed for catalog accuracy, sourcing language, and consistency with our public quality standards. It is an educational summary for research reference only. Read our Editorial Standards.

Ready to order?

Pick your product and check out in under 3 minutes.

Shop Now